Candel Therapeutics Inc (CADL)
10.67
+0.09
(+0.85%)
USD |
NASDAQ |
May 23, 16:00
14.71
+4.04
(+37.86%)
After-Hours: 19:03
Candel Therapeutics Cash from Operations (Quarterly): -8.438M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -8.438M |
| December 31, 2023 | -7.422M |
| September 30, 2023 | -8.808M |
| June 30, 2023 | -7.195M |
| March 31, 2023 | -10.82M |
| December 31, 2022 | -6.885M |
| September 30, 2022 | -9.384M |
| June 30, 2022 | -7.097M |
| March 31, 2022 | -8.053M |
| Date | Value |
|---|---|
| December 31, 2021 | -5.238M |
| September 30, 2021 | -6.894M |
| June 30, 2021 | -4.459M |
| March 31, 2021 | -5.627M |
| December 31, 2020 | -3.416M |
| September 30, 2020 | -1.505M |
| June 30, 2020 | -1.936M |
| March 31, 2020 | -2.214M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-10.82M
Minimum
Mar 2023
-1.505M
Maximum
Sep 2020
-6.199M
Average
-6.894M
Median
Sep 2021
Cash from Operations (Quarterly) Benchmarks
| Allurion Technologies Inc | -8.636M |
| AngioDynamics Inc | -12.53M |
| Eliem Therapeutics Inc | -1.819M |
| Macrogenics Inc | -45.64M |
| GlycoMimetics Inc | -10.51M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.007M |
| Cash from Financing (Quarterly) | -1.255M |
| Free Cash Flow | -32.19M |
| Free Cash Flow Per Share (Quarterly) | -0.2892 |
| Free Cash Flow Yield | -10.40% |